MedTrace Logo

Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer

NCT05686720 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-01-17

No results posted yet for this study

Summary

This study was a single-center, open-label, investigator-initiated clinical trial (IIT) to observe and investigate the clinical safety and efficacy of SZ011 in the treatment of advanced triple-negative breast cancer.

Conditions

  • Advanced Triple Negative Breast Cancer

Interventions

DRUG

SZ011 CAR-NK

In the escalation study, the minimum initial dose was 5.0×10\^6 cells, then increased to 5.0×10\^7 and 2.0×10\^8 cells. The infusion is given every 2 weeks.

Sponsors & Collaborators

  • Guangdong ProCapZoom Biosciences Co., Ltd.

    collaborator INDUSTRY

  • First Affiliated Hospital of Shantou University Medical College

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2024-02-01
Completion
2024-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05686720 on ClinicalTrials.gov